Global medtech revenues reach all-time high, yet innovation investments lag

23 Sep 2019

An increasing number of AI algorithms are now approved by the US Government – a trend that is set to continue as understanding of AI matures.

The global medical technology (medtech) industry continues to grow, but its long-term growth outlook is at risk due to underinvestment in R&D and lack of collaboration between industry providers, payers and patients.

Global medtech revenues reach all-time high, yet innovation investments lag

The 2019 EY medtech report, Pulse of the Industry, has found that in 2018-2019 the industry's collective revenues increased by 7% to US$407.2b, representing medtech's third consecutive year of growth and the highest revenues recorded to date. Valuations were also robust, as cumulative public valuation rose by 38% in the 18 months to 30 June 2019, far outpacing the broader life sciences industry.

While R&D spending increased 11% in 2018, showing promise after a disappointing 2017, uncertainty remains as to whether this rebound signals the beginning of sustained re-investment. The report also notes that cash returned to shareholders increased, with medtech companies returning US$17b to investors in buybacks and dividends – more than the R&D investment total of US$15b.

Pamela Spence, EY Global Health Sciences and Wellness Leader, says: "Medtech remains exciting, as industry players continue to unlock the power of data to offer personalized treatment for more effective and faster patient outcomes. An increasing number of AI algorithms are now approved by the US Government – a trend that is set to continue as our understanding of AI matures. Consolidation into therapeutic areas also continues to build scale, driving companies to be more competitive, while collaboration with non-traditional partners to access diverse skills and talent will be critical to building a cybersecure ecosystem for data exchange between devices or products."

With the absence of a linked-up ecosystem, medtechs cannot extract the full value from the connected devices they create, the report finds.

Jim Welch, EY Global Medtech Leader, says: "Medtechs have a unique opportunity to capitalize on digital transformation. As devices become increasingly connected, medtech companies have a built-in advantage. They also have strong alignment with other health care ecosystem stakeholders, so they are well-placed to develop new business models and create value in the future. What they don't have are broad, in-house capabilities to develop personalized health care offerings. Increased investment in digital collaborations that expand customer experience, as well as data and analytics capabilities, will continue to move medtechs closer to patients."

The report further highlights that medtech companies are continuing to optimize their portfolios to prepare for future growth by shedding non-core assets and increasing capital efficiency. Investment opportunities in the US$500m to US$1b range are limited, exposing the sector to intense competition in innovative fields such as robotic surgery platforms. The report notes that, aside from a small number of megadeals, the total value of mergers and acquisitions is similar to the previous period, albeit spread over a much larger number of deals – indicating that medtechs are prioritizing tuck-ins and portfolio optimization, rather than bold or transformative deals.

Other key findings highlighted in the report include

  • Non-imaging diagnostics signal a growing emphasis on data-driven, personalized and proactive care, recording some of the highest growth in the industry with 11% revenue growth in 2019.
  • Non-imaging diagnostics companies outperformed those offering traditional therapeutic devices, which recorded a 6% revenue growth.
  • Digital health continues to win validation from regulators: in the US, the FDA approved the first augmented reality system for surgical training and more than 30 AI algorithms over the past year.
  • There has been an uptick in medtech M&A deals in Asia-Pacific: despite the total deal value slipping 17% (to just under US$4b) the volume of M&A activity from Asia-Pacific buyers surged 239% to 61 deals – more than the total number of Asia-Pacific-based deals over the 3 previous years combined.
  • Related news

    Finalists announced for this year's CPhI Worldwide Awards

    Finalists announced for this year's CPhI Worldwide Awards

    17 Oct 2019

    The winners’ shortlist is packed with 40 of the industry’s most innovative companies and individuals who are shaping the future of pharma.

    Read more 
    Sanofi opens its first digitally-enabled, continuous manufacturing facility

    Sanofi opens its first digitally-enabled, continuous manufacturing facility

    15 Oct 2019

    One of the first digital manufacturing facilities in the world to use continuous, intensified biologics production technology.

    Read more 
    FDA approves first  and only medicine in a new class of acute treatment for migraine

    FDA approves first and only medicine in a new class of acute treatment for migraine

    15 Oct 2019

    The approval of Eli Lilly's Reyvow represents the first new class of acute migraine treatment approved by the FDA in more than two decades.

    Read more 
    Lonza’s Ibex solutions to support Genmab’s growing clinical portfolio

    Lonza’s Ibex solutions to support Genmab’s growing clinical portfolio

    14 Oct 2019

    Company's Ibex Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 months.

    Read more 
    Funding to accelerate delivery of Univercells' vaccine portfolio

    Funding to accelerate delivery of Univercells' vaccine portfolio

    11 Oct 2019

    European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.

    Read more 
    Industrial-scale manufacture of therapeutic exosomes

    Industrial-scale manufacture of therapeutic exosomes

    10 Oct 2019

    Coordinated purification process development service accelerates progress to clinical trials, and scale-up manufacturing.

    Read more 
    FUJIFILM Irvine Scientific receives CE mark approval for multiple ART media

    FUJIFILM Irvine Scientific receives CE mark approval for multiple ART media

    9 Oct 2019

    Innovative ART products now available in Europe.

    Read more 
    Janssen opens new biomanufacturing building in Ireland

    Janssen opens new biomanufacturing building in Ireland

    8 Oct 2019

    Expansion creates 200 new full-time jobs and increases the company’s production capacity by an additional 19,100 m2.

    Read more 
    BASF and Biomillenia join forces in microbiome research to promote healthy skin

    BASF and Biomillenia join forces in microbiome research to promote healthy skin

    7 Oct 2019

    Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.

    Read more 
    Allergan expands Refresh eye treatment portfolio

    Allergan expands Refresh eye treatment portfolio

    7 Oct 2019

    A trifecta of relief formulated with HydroCell technology offers new artificial tear options for patients suffering from eye dryness.

    Read more